GeoVax Labs Showcases Robust COVID-19 and Mpox Immunogenicity in Clinical Study
GeoVax Labs presents clinical data for GEO-CM04S1 COVID-19 vaccine demonstrating robust immune responses and cross-protection against Mpox. This breakthrough study has significant implications for vaccine development and protection against infectious diseases.
This news matters as it highlights the potential of GEO-CM04S1 to provide dual protection against COVID-19 and Mpox, especially in immunocompromised individuals. The study's findings could lead to the development of more effective vaccines offering broader and durable immunity against current and emerging variants.
